Tags

Type your tag names separated by a space and hit enter

[Critical review of anti-influenza drugs].
Ned Tijdschr Geneeskd 2000; 144(4):165-7NT

Abstract

Neuraminidase inhibitors such as zanamivir and oseltamivir belong to a new class of antiviral drugs for the treatment and prevention of influenza. As yet however, the therapeutic efficacy of these drugs (shortening of recovery time by approximately one day) has only been demonstrated in healthy adults affected by influenza A, but not in risk groups and in influenza B disease, whereas studies of prophylactic efficacy are still going on. Neither do these drugs impact on viral spread, a public health risk against which the economic advantages of early work resumption have to be weighed. Since flu symptoms can be caused by other germs than the influenza A or B virus, caution in prescribing these drugs seems warranted, also to prevent the development of drug resistance. In addition, when designing therapeutic efficacy trials in risk groups, selecting the rate of secondary complications and death may be more adequate as clinical endpoint than (economically important) duration of illness.

Authors+Show Affiliations

College ter beoordeling van geneesmiddelen, Den Haag. fp.v.loon@cbg-meb.nl

Pub Type(s)

English Abstract
Journal Article
Review

Language

dut

PubMed ID

10668542

Citation

van Loon, F P., et al. "[Critical Review of Anti-influenza Drugs]." Nederlands Tijdschrift Voor Geneeskunde, vol. 144, no. 4, 2000, pp. 165-7.
van Loon FP, Voordouw AC, Simonian S, et al. [Critical review of anti-influenza drugs]. Ned Tijdschr Geneeskd. 2000;144(4):165-7.
van Loon, F. P., Voordouw, A. C., Simonian, S., & Koopmans, P. P. (2000). [Critical review of anti-influenza drugs]. Nederlands Tijdschrift Voor Geneeskunde, 144(4), pp. 165-7.
van Loon FP, et al. [Critical Review of Anti-influenza Drugs]. Ned Tijdschr Geneeskd. 2000 Jan 22;144(4):165-7. PubMed PMID: 10668542.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Critical review of anti-influenza drugs]. AU - van Loon,F P, AU - Voordouw,A C, AU - Simonian,S, AU - Koopmans,P P, PY - 2000/2/11/pubmed PY - 2000/3/4/medline PY - 2000/2/11/entrez SP - 165 EP - 7 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 144 IS - 4 N2 - Neuraminidase inhibitors such as zanamivir and oseltamivir belong to a new class of antiviral drugs for the treatment and prevention of influenza. As yet however, the therapeutic efficacy of these drugs (shortening of recovery time by approximately one day) has only been demonstrated in healthy adults affected by influenza A, but not in risk groups and in influenza B disease, whereas studies of prophylactic efficacy are still going on. Neither do these drugs impact on viral spread, a public health risk against which the economic advantages of early work resumption have to be weighed. Since flu symptoms can be caused by other germs than the influenza A or B virus, caution in prescribing these drugs seems warranted, also to prevent the development of drug resistance. In addition, when designing therapeutic efficacy trials in risk groups, selecting the rate of secondary complications and death may be more adequate as clinical endpoint than (economically important) duration of illness. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/10668542/[Critical_review_of_anti_influenza_drugs]_ L2 - https://medlineplus.gov/flu.html DB - PRIME DP - Unbound Medicine ER -